Remicade (infliximab) is a prescription drug that’s used to manage certain autoimmune conditions in adults and some children. The drug is usually given as an intravenous (IV) infusion every 8 weeks.
Celltrion Healthcare is continuing to make the case for switching from intravenous to subcutaneous formulations of infliximab, with the latest data drop suggesting there may be benefits beyond ...
You may get medicines before infliximab to reduce the chance you will have side effects from the infusion. Some people, depending on why they are using infliximab, may be able to change to giving ...
REMICADE ® is an intravenous biologic therapy approved for the treatment of severely active UC, in children and adolescents aged 6 to 17 years, and adult patients with moderately to severely active ...
HORSHAM, PA and KENILWORTH, NJ, NOVEMBER 6, 2007—Centocor, Inc., Schering-Plough Corporation, and Mitsubishi Tanabe Pharma Corporation announced today that an estimated one million patients have now ...
Celltrion is hoping patients make the jump from Johnson & Johnson and Merck blockbuster Remicade to its biosimilar, Remsima--and now it has real-world data to support a switch. In an independent Phase ...
Study showed 73% of Remicade-treated patients with active disease had a clinical response. Centocor Ortho Biotech reported positive data from a Phase III Remicade (infliximab) trial evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback